Literature DB >> 30805937

Wnt1-inducible signaling protein 1 regulates laryngeal squamous cell carcinoma glycolysis and chemoresistance via the YAP1/TEAD1/GLUT1 pathway.

Liang Wang1, Jin Sun1, Pei Gao1, Ke Su1, Huanhuan Wu1, Junli Li1, Weihua Lou1.   

Abstract

Wnt1-inducible signaling protein 1 (WISP1) is a matricellular protein and downstream target of Wnt/β-catenin signaling. This study sought to determine the role of WISP1 in glucose metabolism and chemoresistance in laryngeal squamous cell carcinoma. WISP1 expression was silenced or upregulated in Hep-2 cells by the transfection of WISP1 siRNA or AdWISP1 vector. Ectopic WISP1 expression regulated glucose uptake and lactate production in Hep-2 cells. Subsequently, the expression of glucose transporter 1 (GLUT1) was significantly modulated by WISP1. Furthermore, WISP1 increased cell survival rates, diminished cell death rates, and suppressed ataxia-telangiectasia-mutated (ATM)-mediated DNA damage response pathway in cancer cells treated with cisplatin through GLUT1. WISP1 also promoted cancer cell tumorigenicity and growth in mice implanted with Hep-2 cells. Additionally, WISP1 activated the YAP1/TEAD1 pathway that consequently contributed to the regulation of GLUT1 expression. In summary, WISP1 regulated glucose metabolism and cisplatin resistance in laryngeal cancer by regulating GLUT1 expression. WISP1 may be used as a potential therapeutic target for laryngeal cancer.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Wnt1-inducible signaling protein 1; Yes-associated protein 1; glucose transporter 1; glycolysis; laryngeal squamous cell carcinoma

Year:  2019        PMID: 30805937     DOI: 10.1002/jcp.28253

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

1.  Cell Communication Network factor 4 promotes tumor-induced immunosuppression in melanoma.

Authors:  Audry Fernandez; Wentao Deng; Sarah L McLaughlin; Anika C Pirkey; Stephanie L Rellick; Atefeh Razazan; David J Klinke
Journal:  EMBO Rep       Date:  2022-01-31       Impact factor: 8.807

2.  CAPRIN1 Enhances Chemoresistance and Glycolysis in Laryngeal Squamous Cell Carcinoma via Regulation of ZIC5.

Authors:  Yubo Zhang; Haizhong Zhang; Jinhui Dong; Pengxin Zhao; Fang Hao; Haixia Han; Yanrui Bian
Journal:  J Oncol       Date:  2022-05-05       Impact factor: 4.501

Review 3.  Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence.

Authors:  Shian-Ren Lin; Chia-Hsiang Chang; Che-Fang Hsu; May-Jwan Tsai; Henrich Cheng; Max K Leong; Ping-Jyun Sung; Jian-Chyi Chen; Ching-Feng Weng
Journal:  Br J Pharmacol       Date:  2019-11-27       Impact factor: 8.739

4.  Emetine Synergizes with Cisplatin to Enhance Anti-Cancer Efficacy against Lung Cancer Cells.

Authors:  Ti-Hui Wu; Shan-Yueh Chang; Yu-Lueng Shih; Tsai-Wang Huang; Hung Chang; Ya-Wen Lin
Journal:  Int J Mol Sci       Date:  2019-11-25       Impact factor: 5.923

Review 5.  Overview on Molecular Biomarkers for Laryngeal Cancer: Looking for New Answers to an Old Problem.

Authors:  Michela Falco; Chiara Tammaro; Takashi Takeuchi; Alessia Maria Cossu; Giuseppe Scafuro; Silvia Zappavigna; Annalisa Itro; Raffaele Addeo; Marianna Scrima; Angela Lombardi; Filippo Ricciardiello; Carlo Irace; Michele Caraglia; Gabriella Misso
Journal:  Cancers (Basel)       Date:  2022-03-28       Impact factor: 6.639

Review 6.  Targeting ERK-Hippo Interplay in Cancer Therapy.

Authors:  Karel Vališ; Petr Novák
Journal:  Int J Mol Sci       Date:  2020-05-03       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.